Abivax SA

ABVX · NASDAQ

ABVX is a readout-gated biotech with positive Phase 3 induction data, a much stronger cash position after the 2025 offering, and one big unresolved question: can obefazimod's maintenance data turn runway into a real ulcerative-colitis franchise?

Follow Add to Watchlist Ask Question

NASDAQ ABVX Coverage Bootstrap Biotechnology Ulcerative Colitis Inflammatory Bowel Disease

Latest ReportMay 13, 2026Abivax (ABVX): the ulcerative-colitis readout that has to carry a EUR 530M runwayView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 1 reports match

Clear filters

Add tags

Selected tags

BiotechnologyCoverage Bootstrap

Clear tags

MatchAny tag All tags

Latest Thesis

Abivax (ABVX): the ulcerative-colitis readout that has to carry a EUR 530M runway

May 13, 2026Research reportSlides available

Read report Open slides Discussion (0)

Abivax SA(ABVX): the ulcerative-colitis readout that has to carry a EUR 5May 13, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->

ReportTypeUpdatedReadActions

Abivax (ABVX): the ulcerative-colitis readout that has to carry a EUR 530M runwayABVX is a readout-gated biotech with positive Phase 3 induction data, a much stronger cash position after the 2025 offering, and one big unresolved question: can obefazimod's maintenance data turn runway into a real ulcerative-colitis franchise?NASDAQMay 13, 2026Research reportRead Slides